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Figure captions 
 
Figure 1. Number of articles found on model-based economic evaluations which are 
infection-related and non-infection related. Percentages on top of each bar show the 
proportion of articles that are infection-related. See Appendix for search terms used. 
 
Figure 2. Dynamic and static model predictions about changes to varicella incidence 
following the introduction of an infant immunisation programme (adapted from [46]). 
Initially, following vaccination, there is a honeymoon period where incidence drops rapidly, 
but accumulation of susceptible individuals eventually causes a sharp temporary increase in 
incidence (post-honeymoon epidemic) before infection reaches a new equilibrium (post-
vaccination equilibrium). Assumptions: infant vaccination with 80% coverage and a perfect 
vaccine (100% protection for life).  
 
Figure 3. Timeline for the natural history of infection (a) and disease (b), together with 
corresponding model structures (c). In (c), direct lines indicate movement between health 
states, while dotted lines indicate that the rate at which susceptible individuals are infected is 
influenced by the proportion of the population which is infectious. 
 
Figure 4. Flow diagram showing how the choice of a static model, static model with 
approximation for herd immunity or dynamic model could be made based on answers to 
seven key questions.
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Abstract 
 
The number of economic evaluations related to infectious disease topics has increased over 
the last two decades. However, many such evaluations rely on models which do not take into 
account unique features of infectious diseases which can affect the estimated value of 
interventions against them. These include their transmissibility from infected to susceptible 
individuals, the possibility of acquiring natural immunity following recovery from infection, 
and the uncertainties that arise as a result of their complex natural history and epidemiology. 
Modellers conducting economic evaluations of infectious disease interventions need to know 
the main features of different types of infectious disease models, the situations in which they 
should be applied and the effects of model choices on the cost-effectiveness of interventions. 
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The importance of infectious disease models in pharmacoeconomics 
 
The number of economic evaluations related to infectious disease topics has gradually 
increased over the last two decades, with a database search suggesting that they may now 
account for around 13% of the literature on model-based economic evaluations (see Figure 1 
and Appendix), which are themselves an area rapidly growing in importance [ADD REF: 
Neumann PJ, Fang C-H, Cohen JT. 30 years of pharmaceutical cost-utility analyses. Growth, 
diversity and methodological improvement. Pharmacoeconomics 2009; 27(10):861-72].  
 
Several concurrent trends have contributed to this expansion. Despite large reductions in the 
incidence of infectious diseases over the last 50 years, they are still the second most common 
cause of death worldwide, accounting each year for about 18 million deaths and 600 million 
lost disability-adjusted life years [1]. This burden combined with the risk of high-profile and 
economically damaging outbreaks have ensured their continual importance from a public 
health perspective. Infectious diseases have been kept in the public consciousness as a result 
of emerging diseases such as West Nile virus and human immunodeficiency virus (HIV), 
pandemics such as severe acute respiratory syndrome (SARS) and influenza A/H1N1, the 
threat of bioterrorism and the emergence of antimicrobial-resistant strains of existing 
pathogens. The human and economic impact of an emerging pathogen is difficult to estimate 
but potentially devastating. Additionally, infectious aetiology has been discovered for a 
number of diseases such as hepatitis C and E, peptic ulcers and cervical cancer originally 
thought to be non-communicable. 
 
At the same time, advances in molecular medicine have facilitated the development of new 
tools to prevent and control infectious diseases. The last two decades have been called a new 
“golden age” in the development of vaccines, the most effective intervention we have against 
infectious diseases [2]. The main purchasers of these vaccines have been governments and 
large non-governmental organisations, since they are most effective when used as part of a 
population-level public health programme. Although vaccines are traditionally one of the 
most cost-effective interventions available [ADD REF: World Bank. World Development 
Report 1993. Investing in Health. Oxford: Oxford University Press, 1993.], the high price of 
the new vaccines has resulted in their being subject to greater scrutiny by decision-makers, 
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including pharmacoeconomic evaluation. For instance, there is an increasing role for 
economic evaluation to inform the priorities of global initiatives such as the GAVI Alliance. 
 
Mathematical modelling offers public health planners the ability to make predictions about 
the impact of emerging diseases as well as the effects of possible response and control 
measures. Such models are needed to bridge the gap between clinical trials (which measure 
individual-level efficacy over a short period of time, and for highly selected subpopulations), 
and population-level use. This is particularly crucial for infectious diseases, where mass 
interventions such as vaccination and screening can result in effects on a population-level not 
seen on an individual level, including herd immunity, changes in the epidemiology of 
infection and changes to pathogen ecology as a consequence of selective pressure. 
 
Infectious disease models are in common use in epidemiology, and a well-developed set of 
techniques has been developed over the past few decades to model the epidemiological 
impact of interventions such as vaccination [3]. Since these interventions consume scarce 
health care resources, decision makers are increasingly interested in combining such models 
with pharmacoeconomic techniques in order to investigate whether or not interventions 
provide good value for resources invested. However, despite the expansion in the applied 
literature on economic evaluations of infectious disease interventions, the models 
underpinning such evaluations have not always been used appropriately. Many economic 
evaluations of infectious disease interventions apply models which do not take into account 
the unique complexities of infectious diseases, such as their transmissibility from infected to 
susceptible individuals, the possibility of acquiring natural immunity to infection, and the 
uncertainties that arise as a result of their complex natural history and epidemiology. 
 
Recently, a number of health economists have commented on these shortcomings and urged 
modellers to adopt techniques that are well-established in the infectious disease epidemiology 
literature. A recent systematic review of economic models of Chlamydia screening found that 
almost all inappropriately used static models which failed to take into account onward 
transmission of Chlamydia infection, and hence were likely to incorrectly estimate the cost-
effectiveness of screening [4]. Similar conclusions were drawn in reviews of models of 
hepatitis A [5], hepatitis B [6], varicella [ADD REF: Thiry N, Beutels P, Van Damme P, Van 
Doorslaer E. Economic Evaluations of Varicella Vaccination Programmes. A review of the 
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literature. Pharmacoeconomics 2003; 21(1):13-38.], meningococcal [ADD REF: Kauf TL. 
Methodological Concerns with Economic Evaluations of Meningococcal Vaccines. 
Pharmacoeconomics 2010; 28(6):449-61.]  and human papillomavirus vaccination [7;8]. 
 
This paper is an introduction to the basic types and underlying principles of epidemiological 
modelling of infectious disease interventions, and the way these affect economic evaluations 
built around such models. The review will focus on the issues around modelling the 
epidemiology of infectious diseases, as the normative economic issues around economic 
evaluations of infectious disease interventions have been discussed extensively elsewhere [9-
12]. 
 
A comprehensive taxonomy of decision analytic models has been published [13]. More 
recently the taxonomy was adapted to economic evaluations of vaccination [14]. The 
taxonomy categorises models based on whether (i) states in the model change over time 
(dynamic) or not (static), (ii) changes to the model occur at random (stochastic) or are fixed 
(deterministic), (iii) the model averages the behaviour of populations (aggregate) or tracks 
individuals (individual-based), (iv) events occur in discrete or continuous time, (v) 
individuals can enter or leave the population (open) or not (closed) and (vi) the model’s 
equations are linear or non-linear functions or parameters. This paper highlights  
 some of the key distinctions between types of infectious disease models that are not 
discussed in detail in previous reviews, as well as the way these model features affect their 
estimates of the cost-effectiveness of interventions. Key terms used in this review are defined 
in Box 1 and are indicated by italics when first used in the text. 
 
Interventions that can be modelled 
 
Infectious disease models that are of interest to economists are usually those that estimate the 
effects of an intervention (and hence can be used to evaluate its costs and outcomes), rather 
than simply make predictions about the unfolding of an epidemic or the long-term trends in 
the incidence of an endemic disease. The type of intervention to be evaluated determines the 
type of epidemiological model used to capture key elements of the disease. Some of the most 
common interventions related to infectious disease that have been analysed using economic 
models include the following: 
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 Vaccination. Vaccination has been one of the main areas of application for 
pharmaceconomic models that incorporate models of infectious disease transmission. 
Such transmission models are needed in order to capture the inherent nonlinear effects 
of vaccination, as a result of the potential of vaccines to protect not only directly 
vaccinated individuals but also their contacts. The infectious disease models used to 
predict the effects of vaccination have been reviewed elsewhere [14]. 
 
 Screening. Screening for infected individuals allows them to be treated before they 
progress to more severe disease and/or infect other individuals. Models need to 
incorporate transmission if early detection affects transmissibility. This has been 
shown to be important for many infectious disesases such as Chlamydia [4] and HIV 
[15]. Such models may allow for the possibility that a screened and treated individual 
may be reinfected, which would decrease the cost-effectiveness of screening. 
 
 Social distancing. Planned responses to large outbreaks of infectious diseases such as 
an influenza pandemic often involve social distancing measures such as isolation of 
suspected cases, school closure, travel restrictions and cancellation of mass gatherings 
such as football matches [16][ADD REF: Gojovic MZ, Sander B, Fisman D. 
Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 2009; 181:673-
80]. While these may affect the progress of the epidemic, they come with a cost in 
terms of both individual liberty and economic activity within the population. Their 
benefit depends crucially on the frequency and type of interactions that occur between 
individuals in different age groups and settings (such as families, work places and 
schools). Such information can be obtained from population-based surveys which are 
available in Europe [17] and the United States [18]. On a smaller level, models can 
estimate the impact of isolating infectious individuals during outbreaks in closed 
institutional settings such as hospitals, nursing homes and schools [ADD REF: 
Cooper BS, Medley GF, Stone SP et al. Methicillin-resistant Staphylococcus aureus in 
hospitals and the community: stealth dynamics and control catastrophes. Proc Natl 
Acad Sci USA 2004; 101(27):10223-8][ADD REF: Kelso JK, Milne GJ, Kelly H. 
Simulation suggests that rapid activation of social distancing can arrest epidemic 
development due to a novel strain of influenza. BMC Public Health 2009; 9:117]. 
10 
 
 
 Post-exposure treatment. Chemotreatment options such as antimicrobials can be 
dealt with using static models, unless they alter the transmissibility of an individual, 
or a transmittable characteristic of the infection. Models falling into these categories 
include the use of antiretrovirals for HIV (which increases the life expectancy of 
infected individuals but decreases their infectiousness) [19], antimicrobial use against 
pathogens that can develop resistance [20] and antiviral prophylaxis to delay the 
spread of pandemic influenza [ADD REF: Wu JT, Leung GM, Lipsitch M, Cooper 
BS, Riley S. Hedging against Antiviral Resistance during the Next Influenza 
Pandemic Using Small Stockpiles of an Alternative Chemotherapy. PLoS Medicine 
2009; 6(5): e1000085]. 
 
 Culling. For animal and plant diseases, one option to interrupt transmission is to 
deplete the host population by culling both infected livestock and even healthy 
livestock at risk of being infected. Models examine the trade-off between reduced 
infection transmission and the detrimental death of animals or plants as a result of 
culling. Such models have been applied to epidemics of diseases such as foot-and-
mouth disease [ADD REF: Keeling MJ. Models of foot-and-mouth disease. Proc Biol 
Sci 2005; 272(1569):1195-202] and avian influenza [Truscott J, Garske T, Chis-Ster I 
et al. Control of a highly pathogenic H5N1 avian influenza outbreak in the GB poultry 
flock. Proc R Soc B 2007; 274(1623):2287-95]. 
 
Modelling infection transmission 
 
Types of models. Most infectious diseases are communicable, that is, they are caused by 
agents that can be directly transmitted from host to host. Their communicable nature has 
important effects on the effectiveness of a preventative intervention. This is because the risk 
of acquiring an infection is dependent not only on the individual characteristics of a potential 
host (such as age and whether or not a prophylactic intervention has been received), but also 
on the prevalence of the infection among other people in the population whom a potential 
host may come into contact with. Hence protecting a proportion of people in the population 
from becoming infected can have nonlinear effects on the remainder of the population [21] 
[46]. 
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If the proportion of a population that is susceptible to an infection is sufficiently low (because 
other individuals are either infected, naturally immune to infection or vaccine protected), then 
each infected individual will transmit the disease to less than one susceptible person before 
recovering.  Consequently, the prevalence of the infection will decrease over time. Herd 
immunity is a decrease in the rate of infection in a population in which a large proportion of 
its members are immune, hence reducing the probability that an infected individual will have 
contact with a susceptible individual [21]. The proportion of the population that needs to be 
resistant in order to ensure that an epidemic will not spread (because each infected individual 
transmits the infection to less than one susceptible person) is called the herd immunity 
threshold. Such a concept is vital in models of vaccination programmes, since the aim of 
vaccination is to protect a large enough proportion of the population to eliminate the 
infection. 
 
This has important implications on the way infectious diseases should be modelled. When 
evaluating interventions involving non-communicable diseases, the most common types of 
decision analytic models used by health economists are cohort models, such as decision trees 
and Markov models [22]. These have two main characteristics. Firstly, they usually model a 
closed population (with no individuals allowed to enter the population over time), consisting 
of a single birth cohort. Secondly, the probability of an individual moving between states 
represented by different branches of a decision tree or different transition states of a Markov 
model is dependent only on characteristics of each individual, and not on the number of other 
people who are infectious. For this reason they have been variously called static models [14] 
or models without interaction [13].  
 
For infectious diseases, it is usually more appropriate to use transmission dynamic models. 
These represent an entire population with multiple birth cohorts. The population modelled is 
usually open (with new individuals being created by births), although models over a very 
short time scale may have a single closed population without births. Furthermore, an 
intervention on one individual can have effects on others. This is because the probability of a 
susceptible individual moving to an infectious state depends not only on the proportion of 
people in the susceptible state, but also on the proportion of people in the infected state. The 
instantaneous rate at which susceptible people become infected is called the force of 
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infection. In a static model, the force of infection is constant in time, while in a dynamic 
model it is a function of the proportion of the population that is infected (and hence changes 
over time). 
When to use transmission dynamic models. Compared to static cohort models, 
transmission dynamic models are usually more analytically complex, require more 
epidemiological information to parameterise and demand more computing resources to 
implement. Hence, it is advantageous to use them only when necessary, that is, when an 
intervention can potentially produce significant changes in the force of infection. This can 
occur in several ways. An intervention may decrease the proportion of the population that is 
susceptible, decrease the proportion of the population that is infected or decrease the rate at 
which the infection is transmitted between infected and susceptible people. Examples of each 
of these interventions are vaccinating infants against measles[23], screening for and treating 
tuberculosis carriers in a population [ADD REF: Ziv E, Daley CL, Blower SM. Early therapy 
for latent tuberculosis infection. Am J Epidemiol 2001; 153(4):381-5], and closing schools 
during an influenza pandemic [ADD REF: Hens N, Ayele GM, Goeyvaerts N, Aerts M, 
Mossong J, Edmunds WJ, Beutels P. Estimating the impact of school closure on social 
mixing behaviour and the transmission of close contact infections in eight European 
countries. BMC Infect Dis 2009; 9:187]. An intervention may also cause changes to the 
characteristics of an infectious agent through selective pressure. Examples of this include the 
emergence of antibiotic-resistant strains of bacteria as a result of antibiotic use [20], and the 
increase in prevalence of certain strains of bacteria as a result of vaccination against other 
strains [26] [ADD REF: Melegaro A, Choi YH, George R et al. Dynamic models of 
pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on 
invasive pneumococcal disease. BMC Infect Dis 2010; 1090]. 
 
In an economic model where a preventative intervention such as vaccination, screening or 
social distancing is compared to no intervention, a dynamic model will normally indicate that 
the intervention is more cost-effective compared to an equivalent static model. This occurs 
for two reasons. Firstly, a dynamic model will predict a greater number of infections are 
prevented by the intervention (both those directly protected by the intervention predicted by 
the static model, as well as those indirectly protected through herd immunity). Secondly, a 
dynamic model will predict a faster reduction in the number of infections than a static model, 
which is more beneficial in an economic model with positive time preference. This has been 
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discussed for the case of meningococcal vaccination [Trotter CL, Maiden MCJ. 
Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate 
vaccination programs. Expert Rev Vaccines 2009; 8(7):851-61], and is illustrated for the case 
of an infant varicella vaccination programme in Figure 2. Hence a dynamic model will 
normally predict a more cost-effective outcome, both in the short-term (due to a more rapid 
effect) and also in the long-term (as the effect of herd immunity accumulates over time). 
 
Consequently, if a static model indicates that the intervention is cost-effective, a dynamic 
model will normally show the same. Hence a static model may be sufficient to obtain a 
conservative estimate of cost-effectiveness. However, there are several reasons why a 
dynamic model may still be necessary: 
 
 Even when both static and dynamic models agree on a qualitative prediction (such as 
the favourable cost-effectiveness of an intervention), the dynamic model might 
predict a more complex (and realistic) time course in disease incidence compared to a 
static model. One example is the dynamics of a population following vaccination to a 
level of coverage insufficient to reduce the number of susceptibles below the herd 
immunity threshold. Figure 2 shows how a dynamic model predicts that such a 
vaccination programme can cause the incidence of infection to initially drop to a very 
low level (during a time period called the honeymoon period), but then later show a 
sharp temporary increase due to the accumulation of susceptible individuals during 
the period when the force of infection was low. A real life example is an outbreak of 
rubella in Greece in 1993 following years of low disease incidence after partial 
rubella vaccination [ADD REF: Panagiotopoulos T, Antoniadou I, Valassi-Adam E. 
Increase in congenital rubella occurrence after immunisation in Greece: retrospective 
survey and systematic review. BMJ 1999; 319:1462-7]. None of this behaviour can be 
shown by a static model. This sharp increase can be economically important, because 
it can indicate the need to retain spare health care capacity to accommodate future 
spikes in demand. 
 
 A dynamic model may show that interventions cause changes in the profile of 
infected individuals not seen in a static model. For instance, vaccination reduces the 
force of infection, which causes the average age of infection to increase and the 
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period between any cycles in infection incidence to lengthen. This can be 
economically important. For instance, vaccination against rubella with a low level of 
coverage can cause the average age of rubella infection to increase from childhood to 
child-bearing age, increasing the risk of congenital rubella syndrome which is  a 
condition caused by being born to a mother who had rubella during pregnancy [23]. 
 
 A dynamic model may reveal relationships between variables that are not apparent 
using the static model alone. This is seen in a comparison between static and dynamic 
models of therapeutic antiviral use in the Netherlands during an influenza pandemic 
[24]. Both models predicted that the intervention would be cost-effective; however, 
the dynamic model suggested that the cost-effectiveness ratio would be sensitive to 
the size of the pandemic whereas the static model did not show this relationship. 
 
 When one preventative intervention is compared to another, a dynamic model does 
not necessarily give a more cost-effective result than a static model, since it will 
predict that both options have a greater effect than predicted by a static model. An 
example of this is using economic modelling to determine the appropriate age for a 
catch-up vaccination campaign, which requires comparing several catch-up 
vaccination strategies covering different age ranges [25]. 
 
 Some diseases are caused by several types or subtypes of organisms, and 
interventions can induce selective pressures which cause a subset of these types to 
gain a fitness advantage over others. Examples are replacement of one type of bacteria 
by another following vaccination [26][ADD REF: Melegaro A, Choi YH, George R et 
al. Dynamic models of pneumococcal carriage and the impact of the heptavalent 
pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect Dis 
2010; 1090] and emergence antimicrobial resistant respiratory tract infections 
following antibiotic use [20]. A dynamic model with multiple types can predict long-
term emergent behaviour that will not be seen in static models. Such a model usually 
incorporates a competition parameter that measures the ability of one strain to infect a 
host who is already infected by another strain. 
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On the other hand, dynamic models are unnecessary when interventions have no effect on the 
force of infection on people not receiving the intervention. One such case is that of infections 
such as rabies and West Nile virus which have environmental reservoirs largely unaffected by 
the proportion of infected people in the population. An intervention targeting human hosts 
rather than animal or insect reservoirs will have little effect on the force of infection. The 
same is true for interventions affecting the severity of disease in infected people but not their 
transmissibility, such as end-of-life therapy for cervical cancer which does not significantly 
affect the transmission of the causative infective agent (human papillomavirus), since this 
occurs decades before the development of cancer. Another example is that of a vaccine which 
prevents individuals from getting disease from an infection but does not prevent them from 
acquiring the infection asymptomatically. For instance, early economic models of 
pneumococcal [27] and rotavirus [28] vaccination were largely static because it was not 
known whether vaccination would prevent asymptomatic transmission. More recently, 
however, evidence has emerged that the vaccines may also prevent transmission [ADD REF: 
Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal 
disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 
2005; 294(16);2043-51.][ADD REF: Centers for Disease Control Prevention. Delayed onset 
and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. 
MMWR Morb Mortal Wkly Rep 2008;57(June 25):697-700.], so more recently dynamic 
models of vaccination incorporating herd immunity have been developed [ADD REF: 
Melegaro A, Choi YH, George R et al. Dynamic models of pneumococcal carriage and the 
impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal 
disease. BMC Infect Dis 2010; 1090][ADD REF: Shim E, Galvani AP. Impact of 
transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009; 
27(30);4025-30]. 
 
Approximating herd immunity in static models. One method that has been used to avoid 
the complexity of dynamic models is to retain a static cohort model structure, but then to 
approximate the population effect of an intervention from the experience of another similar 
population which has undergone the intervention, or from the results of a dynamic model 
used in a different situation. There are several examples of this from economic evaluations of 
vaccination. Static cohort models used to estimate the cost-effectiveness of pneumococcal 
vaccination in England [29], and of meningococcal C vaccination in Quebec [30] were 
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extended using information from post-vaccination surveillance in the United States to 
estimate the population-level impact. Similarly, the indirect benefit of pertussis vaccination 
was estimated in a cohort model of pertussis vaccination [31] by using equilibrium values of 
a separate dynamic model. Besides evaluations of vaccination, some cost-effectiveness 
evaluations of HIV screening have assumed a fixed reduction in secondary cases from 
detecting and treating a primary HIV case [32]. 
 
There are a number of dangers with this approach. Firstly, it requires the use of estimates 
from either a dynamic model or surveillance conducted in a different population or situation, 
since it would be unnecessary to use a model at all if there was already good information on 
the long-term effect of an intervention in the same population. However, differences between 
populations (such as in age profile, likely uptake of the intervention, size of age and risk 
groups or mixing frequency between individuals in the population) may alter an 
intervention’s effect in unpredictable ways. For instance, post-marketing surveillance 
following the introduction of pneumococcal vaccination in England and Wales revealed a 
level of serotype replacement not seen in US surveillance data [33]. Secondly, estimating 
herd immunity benefit from the equilibrium state of a dynamic model ignores the period of 
change between the start of an intervention and reaching the equilibrium, when disease 
prevalence may fluctuate. This can be extremely important in an economic evaluation with 
positive time preference, since the initial period is closer in time to the intervention and hence 
the costs and benefits accrued during this period are more influential. Because of these 
reasons, this technique should ideally be used only when construction of a population-
specific transmission dynamic model is restricted by data limitations, and even then, a wide 
range of possible scenarios for key parameters governing the differences in the populations 
being modelled should be considered. Also, more sophisticated approximations could be used 
than simply applying the equilibrium state of a dynamic model from the start of an 
intervention. For example, one method of approximating herd immunity has been proposed 
which retain a cohort structure but take into account a gradual reduction in the force of 
infection until a post-vaccination equilibrium is reached [ADD REF: Bauch CT, Anonychuk 
AM, Effelterre TV et al. Med Decis Making 2009; 29:557-69]. 
 
Figure 4 is a flow diagram with an algorithm with key questions that need to be asked when 
choosing between different types of models to investigate an infectious disease intervention. 
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Modelling the natural history of infection and disease 
 
This section provides a brief description of the features of infectious disease natural history 
most relevant to modelling; further details are available elsewhere [ADD REF: Kramer A, 
Akmatov M, Kretzschmar M. Principles of Infectious Disease Epidemiology. In: Modern 
Infectious Disease Epidemiology. Concepts, Methods, Mathematical Models, and Public 
Health (eds: A Kramer, K Krickeberg, M Kretschmar). New York: Springer Science and 
Business Media, 2010]. 
 
There are many stages of infection and disease (see Figure 3(a)-(b)). Both infection and 
disease begin with the exposure of a susceptible host to the infectious agent. If the host is 
infected, then the latent period begins, followed by the infectious period when the individual 
is infectious to others. The length of the latent period can vary from several days (influenza) 
to decades (tuberculosis). The final stage is the one where the host is removed from the 
infected population, through recovery or death.  
 
Different stages of disease also commence at the time of infection. This first stage of disease, 
the incubation period, usually lasts until partway through the infectious period, and is 
followed by the symptomatic period. However, some infections may simply result in 
asymptomatic infection rather than disease. Although the purpose of an intervention is 
ultimately to reduce the burden of disease rather than infection, transmission models need to 
take into account unreported cases (both asymptomatic and symptomatic) as these contribute 
to infection transmission and hence affect the consequences of interventions. One example is 
the 2009 influenza pandemic, where the number of cases of symptomatic disease were 
reduced by widespread asymptomatic infection leading to natural immunity in the population 
[ADD REF: Baguelin M, van Hoek AJ, Jit M et al. Vaccination against pandemic influenza 
A/H1N1v in England: a real-time economic evaluation. Vaccine 2010; 28:2370-84]. 
 
An individual who recovers from infection may develop natural immunity. Most 
epidemiological models do not attempt to capture the detailed biological mechanisms of 
immune response, but instead make one of several assumptions about natural immunity, 
illustrated in Figure 3(c): 
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 SIS (susceptible-infectious-susceptible) models assume that no natural immunity 
occurs, so individuals who recover from infection are immediately susceptible to 
further infections of the same kind. This is the simplest option and may be appropriate 
to represent diseases such as gonorrhoea that do not confer immunity, usually because 
they are caused by pathogens that are highly diverse or evolve rapidly to avoid 
immune defences. 
 
 SIR (susceptible-infectious-recovered) models assume that a host can only be infected 
once in an individual’s lifetime (or the time horizon of the model). This is appropriate 
for representing diseases such as measles for which natural immunity is close to 
lifelong. 
 
 SIRS (susceptible-infectious-recovered-susceptible) models assume that a host is 
protected from re-infection for some time after recovering, but that this natural 
immunity to infection wanes over time. This is appropriate for modelling infection by 
a virus such as influenza, which continuously changes over time so that natural 
immunity to a particular season’s strain is lost after a few years. 
 
 SEIR (susceptible-exposed-infectious-recovered) models are a modification of SIR 
models to include a latent period during which an individual is infected but does not 
transmit infection.  This is important in infectious disease dynamics since it 
introduces a delay which reduces the speed at which an epidemic spreads through a 
population. This can also represent a phase when the host is infectious but without 
symptoms, which may be important if individuals are expected to change their 
contacts patterns after the onset of symptoms. Note that SEIS and SEIRS models are 
also possible by incorporating a latent period into SIS and SIRS models. 
 
The way natural immunity is modelled has an influence on the cost-effectiveness of an 
intervention. An intervention such as vaccination against an infection will have the largest 
effect, and hence be most cost-effective, in a model where natural immunity to the infection 
is modelled using an SIR model, and the least effect when using on an SIS model [34]. This 
is because natural immunity creates a pool of individuals already resistant to the infection, 
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and hence anyone who has been infected before can no longer benefit from vaccination. 
Often, the choice of model to represent natural immunity is not straightforward because of 
lack of data on the existence and persistence of natural immunity. 
 
Incorporating uncertainty into models 
 
In order to evaluate the effects of an intervention, infectious disease models first need to be 
calibrated to pre-intervention epidemiology by choosing suitable parameters representing 
infectivity and immunity. Next, the intervention is introduced, either by altering these 
parameters or by introducing new model states to represent directly affected individuals. 
 
These steps rely on assumptions that are often inherently uncertain. The most common way 
of accounting for this uncertainty is to vary key parameters in a model across their plausible 
distributions, either in a univariable fashion or together [35], and to see the effect this has on 
the predictions of the model. Several authors discussing both infectious disease models 
[11;36] as well as economic models in general [37;38] have pointed out that this only takes 
into account parametric uncertainty. Other forms of uncertainty that have been proposed 
include model uncertainty, structural uncertainty and methodological uncertainty. Here we 
discuss the relevance of different sources of uncertainty in pharmacoeconomic models of 
infectious diseases, as well as appropriate ways to account for them. 
 
Parametric uncertainty. Parametric uncertainty refers to variation in the numerical input 
values of a decision analytic model. These parameters may include transition rates between 
health states, values governing the efficacy of interventions, as well as cost and utility 
weights associated with health states.  
 
Parametric uncertainty occurs when parameters are estimated from the results of 
epidemiological and economic studies that are subject to both sampling error, and to lack of 
validity (bias) due to differences in modelled and actual study populations. Probabilistic 
sensitivity analysis is often considered the best method of accounting for uncertainty in the 
joint distribution of the parameters; for example, it is required in economic evaluations 
commissioned by the UK’s National Institute for Health and Clinical Excellence [39].  
However, probabilistic sensitivity analysis can be particularly challenging to conduct for 
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infectious disease models. Key parameters in these models include the contact rates between 
different individuals (for example, individuals in different age or risk groups) and the 
probability that an infected individual will transmit an infection to a susceptible individual 
during a contact. Until recently, contact rates were difficult to quantify and were estimated by 
imposing a simple age structure on the model, and fitting the contact rates to data about the 
current infection status of a population [ADD REF: Anderson RM, May RM. Age-related 
changes in the rate of disease transmission: implications for the design of vaccination 
programmes. J Hyg 1985; 94:365-436]. Recent population-based contact surveys have 
measured contact rates relevant to airborne or close contact infections directly [ADD REF: 
Mossong J, Hens N, Jit M et al. Social Contacts and Mixing Patterns Relevant to the Spread 
of Infectious Diseases. PLoS Med 2008; 5:381-91]. However, they are subject to sampling 
and measurement error, and still require the probabilities of transmission for different types 
of contacts (such as close-contact or airborne) to be known. Hence the uncertainty in both 
contact rates and transmission probabilities needs to be captured in a way that incorporates 
their relatedness to each other. One method to capture is to sample directly from the space of 
individual contacts in contact surveys as well as current infection status surveys, thus 
obtaining a joint distribution representing the uncertainty in both. Next, the probability of 
transmission is chosen that enables the model to fit data about the current infection status of a 
population [40][ADD REF: Zagheni E, Billari FC, Manfredi P. Using time-use data to 
parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 
2008; 168(9):1082-90]. 
 
Structural uncertainty. Structural uncertainty refers to different choices of health states in a 
model and relationships between them. For instance, natural immunity following recovery 
from infection can be modelled using different possible structures such as SIS, SIR and SIRS 
(Figure 3(c)). All three structures can be successfully fitted to outcome data by appropriately 
adjusting the force of infection. However, an SIS structure will predict that a preventative 
measure such as vaccination with long-term duration of protection has the greatest impact 
(and is most cost-effective), while a SIR structure will predict the least impact [34]. One way 
of dealing with structural uncertainty is by parameterising the range of choices and then 
averaging outcomes as these structural parameters are varied [38]. In the case of natural 
immunity, the duration of natural immunity could be considered a parameter that is varied 
over a plausible range. This range could potentially take values between zero and the lifetime 
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of the individual, so that an SIS model corresponded to a value of zero, SIR to a value of 
infinity and SIRS to intermediate values. Hence, many forms of structural uncertainty can be 
reduced to parametric uncertainty. In practice however, many models are constructed that do 
not parameterise all plausible model choices that fit the understanding of the disease being 
modelled. Consequently, the usual techniques for accounting for parametric uncertainty may 
underestimate uncertainty. 
 
Model uncertainty. Model uncertainty refers to variation that arises as a result of different 
categorical choices that cannot be readily parameterised. For instance, Brisson and Edmunds 
[36] discuss a series of models of varicella vaccination involving several model choices: (i) a 
choice between static and dynamic models, (ii) a choice between a model where exposure to 
a person infected with varicella reduced an individual’s risk of zoster (another disease caused 
by reactivation of the same virus in previously infected individuals), and one without such an 
effect. Neither choice can be reliably parameterised. The first is a decision to use either a 
simplified model or a more complex but potentially more realistic one, based on 
considerations such as those discussed elsewhere in this paper. The second depends on 
modellers’ belief in a hypothesis for which there is some epidemiological evidence [41] but is 
by no means completely accepted. In this case, it may be weight different model choices and 
use model averaging over the range of choices [38]. 
 
Methodological uncertainty. Methodological uncertainty refers to variations that arise as a 
result of different choices for model values due to normative issues rather than as a result of 
the difficulty in reflecting objective reality. Such considerations include the appropriate 
discount rates to apply, the type of economic analysis (such as cost-effectiveness or cost-
benefit), the time horizon and the analytical perspective to use. These choices are often made 
based on a “reference case” that decision making bodies adopt [42] to reflect societal 
preferences on issues such as time preference and equity tradeoffs between different sectors 
of society. However, these guidelines are usually written with non-infectious diseases in 
mind. Indeed, most country-specific guidelines for economic evaluations do not specifically 
discuss infectious diseases, although Australian guidelines have a vaccine-specific appendix 
that discusses the need to consider herd immunity [ADD REF: Nolan TM. The Australian 
model of immunization advice and vaccine funding. Vaccine 2010; 28S:A76-A83], and the 
World Health Organization has a guide for standardising evaluations of vaccination 
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programmes [ADD REF: Walker DG, Hutubessy R, Beutels P. WHO guide for 
standardisation of economic evaluations of immunization programmes. Vaccine 2010; 
28(11):2356-9]. Because of their unique characteristics, these methodological choices can 
have large effects on the results of economic evaluations of infectious disease interventions 
that are not always predictable from their effects on other interventions [43]. 
 
One example is the issue of the time horizon over which costs and outcomes are assessed. A 
lifetime time horizon is usually appropriate for evaluating interventions for chronic non-
infectious diseases in which no further costs or health benefits are incurred after the death of 
the recipient of the intervention. However, for an intervention for an infectious disease such 
as vaccination, wider costs and benefits can continue to accrue long after the lifetime of the 
person receiving it. Indeed, infectious disease interventions can cause permanent changes to 
pathogen ecology (such as eradication or evolution). Hence the choice of time horizon is 
crucial, and difficult to establish. This is illustrated by the case of varicella vaccination 
[36][44], where a short time horizon causes vaccination to appear less cost-effective because 
of the increase in cases of zoster in older unvaccinated adults as a result of reduced immune 
boosting from contact with people infected with varicella. For a longer time horizon however, 
the intervention becomes increasingly cost-effective because zoster incidence decreases as 
the vaccinated cohorts are protected from shingles in later life. Apart from the time horizon, 
interventions with outcomes that occur many years after the intervention (such as vaccination 
against human papillomavirus or hepatitis B) are also highly sensitive to choice of discount 
rates [ADD REF: Beutels P, Schuffham PA, MacIntyre CR. Funding of drugs: do vaccines 
warrant a different approach? Lancet Infect Dis 2008; 8(11):727-33][ADD REF: Brisson M, 
Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in 
developed countries. Public Health Genomics 2009; 12(5-6):343-51]. 
 
Another example is the strong externalities associated with communicable diseases because 
of the possibility that an infected individual will spread the infection to others. Hence, 
interventions such as vaccination and social distancing may have benefits to people other 
than the individual receiving the intervention (and possibly net disbenefits to the direct 
recipient). Furthermore, the impact of preventing or mitigating pandemics such as SARS, 
influenza and HIV on the wider economy may be considered by decision-makers to be more 
important than the actual health impact [45][ADD REF: Lamontagne E, Haacker M, 
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Ventelou B, Greener R. Macroeconomic impact of HIV: the need for better modelling. Curr 
Opin HIV AIDS 2010; 5(3):249-54]. Hence perspectives that are limited to health sector 
costs and outcomes may ignore what are considered the most important benefits of certain 
infectious disease interventions. 
 
Conclusion 
 
Economic evaluations of infectious disease interventions are likely to continue to play an 
important role in decision making. However, modellers conducting such evaluations need to 
understand the unique features of the disease and intervention they are modelling, as well as 
the appropriate choices of models to use. 
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Appendix. Strategy used for database search exercise. 
 
Database searched: Ovid MEDLINE(R) 
 
Date of searching: 17 April 2010 
 
Search terms used: 
 
All economic evaluations 
1. Economics/ 
2. exp Economics, Dental/ 
3. exp Economics, Hospital/ 
4. exp Economics, Medical/ 
5. exp Economics, Nursing/ 
6. exp Economics, Pharmaceutical/ 
7. cost$.mp. 
8. economic$.mp. 
9. pharmacoeconomic$.mp. 
10. or/1-9 
11. model$.mp. 
12. Models, Economic/ 
13. Models, Theoretical/ 
14. Decision Support Techniques/ 
15. Markov Chains/ 
16. Computer Simulation/ 
17. simulation$.mp. 
18. Decision Trees/ 
19. decision tree$.mp. 
20. or/10-19 
21. 10 and 20 
 
Infection-related economic evaluations: 
22. Communicable Diseases/ 
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23. infection/ 
24. infect$.mp. 
25. bacter$.mp. 
26. viral.mp. 
27. virus.mp. 
28. helminth$.mp. 
29. or/22-28 
30. 21 and 29 
 
Titles of articles returned were examined briefly to ensure that the search terms appeared 
valid, but no attempt at systematic screening was made. Hence the reported number of 
articles returned should be regarded as indicative of the literature rather than exact.
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Box. Glossary of key terms used in infectious disease modelling. 
 
Aggregate (compartmental) model. Model which is divided into various compartments 
representing the average state of individuals assigned to that compartment. Within a single 
compartment, all individuals are considered to be identical (homogeneous). 
 
Catch-up vaccination campaign. Programme in which vaccination is offered initially to age 
cohorts above the age of routine vaccination in order to rapidly increase the proportion of the 
population who is vaccine protected. 
 
Closed population. Model population which is fixed in size, and in which no new 
individuals can enter or leave. 
 
(Single) cohort model. Model of a closed population consisting of a single birth cohort, 
usually with a fixed force of infection (and hence static). 
 
Communicable disease. A disease caused by an infection that can be transmitted directly 
from host to host. 
 
Competition parameter. Parameter in a transmission dynamic model measuring the ability 
of one type or subtype of pathogen to infect a host that is already infected by another type or 
subtype. 
 
Deterministic model. Model in which each iteration with the same input parameters and 
initial conditions will generate exactly the same output, because there is no source of 
randomness (stochasticity) within the model. 
 
(Transmission) dynamic model. Model of an entire population with multiple birth cohorts, 
and a force of infection varying depending on the proportion of the population who are 
infected. The population may be stratified into different subgroups (by age, risk factors or 
other demographic attributes) based on each group’s susceptibility to infection and 
probability of contact with other subgroups. 
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Force of infection. The instantaneous rate at which susceptible people become infected. 
 
Herd immunity. The resistance to infection of a population in which a large proportion of its 
members are immune, hence reducing the probability that an infected individual will have 
contact with a susceptible individual. 
 
Herd immunity threshold. The proportion of the population that needs to be resistant in 
order to ensure that an epidemic will not spread. 
 
Honeymoon period. Initial time period following vaccination when infection incidence 
drops to a very low level before subsequently rising. 
 
Incubation period. Time from an initial infection to the start of symptomatic disease, during 
which the host has no symptoms. 
 
Individual-based model. Model in which each individual has its own characteristics rather 
than being assigned to homogeneous compartments based on average states of groups of 
individuals. 
 
Infection. Acquisition by a host of the agent (such as a bacterium or virus) that can 
potentially cause the disease. 
 
Infectious period. Time during which an infected individual can transmit the infectious 
agent to others. 
 
Latent period. Time period from an initial infection to the start of the infectious period, 
during which an infected individual does not transmit the infectious agent to others. 
 
Natural immunity. The potential of a host’s acquired immune system to develop 
mechanisms after a first infection that reduce the risk of the same type of pathogen infecting 
the host again. 
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Open population. Model population in which new individuals can enter or leave the model 
(for instance, through births, deaths, immigration and emigration). 
 
Static model (or model without interaction). Model with a force of infection that is 
independent of the proportion of the population that is infected. These are usually single 
cohort models. 
 
Stochastic model. Model in which two iterations with the same input parameters and initial 
conditions may generate different outputs, because there is a source of randomness 
(stochasticity) within the model itself that determines whether or not events occur. 
 
Symptomatic period. Time during which an infected individual has symptoms. 
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Figure 4 
 
Q2. Is the disease directly transmitted between humans, and 
does the intervention affect its potential for transmission?
Q1. Is the intervention likely to affect the ecology of the causal 
micro-organism or its host (for example, by causing serotype 
replacement or antibiotic resistance)?
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